*2.1. Materials*

Sage (*Salvia officinalis* L.) was supplied by the Institute for Medicinal Plants Research "Dr. Josif Panˇci´c" (Belgrade, Serbia). Poly(ε-caprolactone) (Mn=80,000), 2,2-diphenyl-1-picrylhydrazyl (DPPH), (±)-6-hydroxy-2,5,7,8-tetramethylchroman-2-carboxylic acid (Trolox) and D-limonene were obtained from Sigma Aldrich (St. Louis, MO, USA). Ethanol, chloroform, butanol, and methanol were purchased from Panreac Quimica SLU (Barcelona, Spain). Müller Hinton Broth and Agar (MHB and MHA) were provided by Merck KGaA (Darmstadt, Germany). Resazurin sodium salt was procured from MP Biomedicals, LLC (Solon, OH, USA). Phosphate buffered saline (PBS) was purchased from Amresco, LLC (Cleveland, OH, USA). All chemicals were used as received without any further purification.

#### *2.2. Preparation of Sage Extract*

Sage extract (SE) was prepared by maceration. An aqueous solution of ethanol (50% *v*/*v*) was used as extraction medium. Drug to solvent ratio was 1:20. The extraction process was carried out on an orbital shaker (Stuart SSL1, Staffordshire, UK) with continuous agitation fixed at 200 rpm for 90 min at room temperature. The obtained extract was filtered through a medical gauze and the solvent was evaporated by casting in a fume hood (Flores Valles, Madrid, Spain). Sage extract powder was stored under refrigeration conditions prior to use.

#### *2.3. Characterization of Sage Extract*
